We are live on ! Find out more
BCLI

BRAINSTORM CELL THERAPUTC
BCLI

Delisted

BCLI was delisted on the 17th of July, 2025.

Back to rankings

23 hedge funds and large institutions have $4.28M invested in BRAINSTORM CELL THERAPUTC in 2015 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

10% more funds holding

Funds holding: 21 → 23 (+2)

3% less capital invested

Capital invested by funds: $4.39M → $4.28M (-$113K)

Holders
23
Holders Change
+2
Holders Change %
+9.52%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ARTA
A.R.T. Advisors
New York
+$83.4K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$35.4K
3
LPL Financial
LPL Financial
California
+$27.5K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$8.24K
5
BFA
BlackRock Fund Advisors
California
+$5.64K

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$916K
2
SM
Sabby Management
Florida
-$227K
3
Simplex Trading
Simplex Trading
Illinois
-$4K
4
TRCT
Tower Research Capital (TRC)
New York
-$2.68K

BCLI Hedge Fund Activity: Q4 2015 in Review

23 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q4 2015, worth a combined $4.28M — down 2.6% from $4.39M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new BCLI positions and 3 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was A.R.T. Advisors, opening a new position worth an estimated $83.4K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $916K sold.

  • 23 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q4 2015, up from 21 in Q3 2015.
  • Funds reported $4.28M of BRAINSTORM CELL THERAPUTC stock for Q4 2015, down 2.6% quarter-over-quarter.
  • 5 funds opened new BRAINSTORM CELL THERAPUTC positions in Q4 2015 and 3 closed out, a net change of +2 holders.
  • The largest BRAINSTORM CELL THERAPUTC buyer in Q4 2015 was A.R.T. Advisors, an estimated $83.4K added.
  • The largest BRAINSTORM CELL THERAPUTC seller in Q4 2015 was Perceptive Advisors, an estimated $916K sold.

Based on aggregated 13F filings for Q4 2015.